Preclinical animal models of multiple myeloma
- 3 February 2016
- journal article
- Published by Portico in BoneKEy Reports
- Vol. 5, 772
- https://doi.org/10.1038/bonekey.2015.142
Abstract
Multiple myeloma is an incurable plasma-cell malignancy characterized by osteolytic bone disease and immunosuppression. Murine models of multiple myeloma and myeloma bone disease are critical tools for an improved understanding of the pathogenesis of the disease and the development of novel therapeutic strategies. This review will cover commonly used immunocompetent and xenograft models of myeloma, describing the advantages and disadvantages of each model system. In addition, this review provides detailed protocols for establishing systemic and local models of myeloma using both murine and human myeloma cell lines.Keywords
This publication has 55 references indexed in Scilit:
- 18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomibBlood Cancer Journal, 2013
- Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myelomaCell Death & Disease, 2013
- BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progressionJCI Insight, 2013
- Molecular pathogenesis of multiple myeloma and its premalignant precursorJCI Insight, 2012
- A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cellsLeukemia, 2011
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center MalignanciesCancer Cell, 2008
- The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma PathogenesisCancer Cell, 2007
- A novel proteasome inhibitor NPI-0052 as an anticancer therapyBritish Journal of Cancer, 2006
- Mechanisms of Bone MetastasisThe New England Journal of Medicine, 2004
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985